NAS:MNTA (USA) Also Trade In: Germany
Momenta Pharmaceuticals Inc $ 52.33 0.04 (0.08%)
Warning! GuruFocus has detected 4 Severe warning signs with MNTA. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Momenta Pharmaceuticals Inc () from 2004 to Sep 24 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Momenta Pharmaceuticals stock (MNTA) PE ratio as of Sep 24 2020 is 0. More Details
Momenta Pharmaceuticals PE Ratio (TTM) Historical Data
View and export this data going back to 2004. Start your Free Trial
Momenta Pharmaceuticals PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NYSE:EBS NYSE:TARO OTCPK:NUNZ NAS:IRWD NAS:PCRX OTCPK:BKUH NYSE:AMRX NAS:TCDA NAS:TLRY NAS:SUPN NYSE:ZTS TSE:4502 XTER:MRK HKSE:03692 TSE:4523 SZSE:000661 TSE:4507 SZSE:000538 NSE:SUNPHARMA SZSE:300601
Address 301 Binney Street, Cambridge, MA, USA, 02142
Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.